Combined Approach to Lysis Utilizing Eptifibatide and Recombinant Tissue-Type Plasminogen Activator in Acute Ischemic Stroke-Full Dose Regimen Stroke Trial [Clinical Sciences]

Conclusions— These results demonstrate comparable safety of full-dose r-tPA plus eptifibatide with historical rates of sICH with r-tPA alone and support proceeding with a phase 3 trial evaluating full-dose r-tPA combined with eptifibatide to improve outcomes after AIS.

http://stroke.ahajournals.org/cgi/content/short/46/9/2529?rss=1

Source: Stroke - August 24, 2015 Category: Neurology Authors: Adeoye, O., Sucharew, H., Khoury, J., Vagal, A., Schmit, P. A., Ewing, I., Levine, S. R., Demel, S., Eckerle, B., Katz, B., Kleindorfer, D., Stettler, B., Woo, D., Khatri, P., Broderick, J. P., Pancioli, A. M. Tags: Acute Cerebral Infarction, Emergency treatment of Stroke, Thrombolysis Clinical Sciences Source Type: research